Handelsbanken Fonder AB Acquires 13,900 Shares of Exelixis, Inc. $EXEL

Handelsbanken Fonder AB boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 21.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 79,866 shares of the biotechnology company’s stock after purchasing an additional 13,900 shares during the quarter. Handelsbanken Fonder AB’s holdings in Exelixis were worth $3,298,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Richardson Financial Services Inc. boosted its position in shares of Exelixis by 95.1% in the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 292 shares in the last quarter. Root Financial Partners LLC bought a new position in Exelixis during the 3rd quarter valued at approximately $28,000. Luminist Capital LLC raised its stake in Exelixis by 2,740.0% during the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 685 shares during the last quarter. Abich Financial Wealth Management LLC bought a new stake in Exelixis in the third quarter worth $47,000. Finally, Hantz Financial Services Inc. boosted its holdings in Exelixis by 940.4% in the second quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 1,025 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Key Stories Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks published a positive takecalling EXEL a “Top Value Stock for the Long-Term,” which supports a longer-term, value-oriented bull case for investors focused on valuation and cash flow. Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Morgan Stanley reiterated a Hold rating and kept its $49 price target, noting that while Welireg competition tempers RCC upside, the embedded cabozantinib franchise still provides support — a mixed view that keeps sentiment neutral. Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
• Neutral Sentiment: Benzinga and other roundups compiling multiple analyst projections provide a range of views (some bullish on long-term value, others cautious), meaning consensus remains mixed and investors should focus on which revenue scenarios play out. Forecasting The Future: 11 Analyst Projections For Exelixis
• Neutral Sentiment: Reported short-interest items show zero shares or inconsistent data (likely a reporting/data error), so there’s no clear short-squeeze signal to factor into near-term price action. (Market-impact: negligible until cleaned up.)
• Negative Sentiment: Royal Bank of Canada cut its price target to $43 and set a “sector perform” rating, signaling reduced upside expectations and likely contributing to downward pressure on the stock. Exelixis (NASDAQ:EXEL) Price Target Lowered to $43.00 at Royal Bank Of Canada
• Negative Sentiment: An investing.com item notes EXEL stock fell after a Merck trial produced stronger results versus competing approaches — competitive clinical data can reduce Exelixis’ market share and near-term growth prospects in relevant indications. Exelixis stock falls after rival Merck trial shows better results
• Negative Sentiment: Stifel reiterated a Hold rating, explicitly flagging emerging belzutifan competition and uncertain cabozantinib revenue visibility — commentary that reinforces cautious analyst positioning. Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
• Negative Sentiment: Wall Street Zen lowered its stock rating, another data point adding to negative near-term sentiment from some retail/independent research outlets. Exelixis (NASDAQ:EXEL) Stock Rating Lowered by Wall Street Zen

Analyst Ratings Changes

Several equities analysts have recently weighed in on EXEL shares. UBS Group set a $41.00 price target on Exelixis in a report on Monday, January 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Barclays lifted their target price on shares of Exelixis from $41.00 to $44.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Truist Financial set a $51.00 target price on shares of Exelixis in a research note on Wednesday, January 14th. Finally, Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and an average target price of $46.94.

Insider Activity at Exelixis

In other news, EVP Patrick J. Haley sold 67,814 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the completion of the sale, the executive vice president owned 381,908 shares of the company’s stock, valued at $16,620,636.16. This represents a 15.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher J. Senner sold 30,617 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.67, for a total transaction of $1,337,044.39. Following the completion of the transaction, the chief financial officer directly owned 976,092 shares in the company, valued at approximately $42,625,937.64. The trade was a 3.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 362,849 shares of company stock valued at $15,917,463 in the last 90 days. 2.85% of the stock is owned by company insiders.

Exelixis Trading Down 0.7%

Shares of EXEL stock opened at $40.74 on Wednesday. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62. The stock has a market capitalization of $10.58 billion, a P/E ratio of 14.71, a P/E/G ratio of 0.92 and a beta of 0.41. The firm’s 50 day moving average is $43.87 and its 200 day moving average is $41.52.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. The business had revenue of $598.66 million during the quarter, compared to analyst estimates of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.55 EPS. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.